FlotteT, CarterB, ConradC, et al.A Phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther, 1996; 7:1145–1159.
2.
TerryM.Two patient deaths halt Audentes' gene therapy trial. June 29, 2020. https://www.biospace.com/article/2-patient-deaths-halt-audentes-gene-therapy-trial/ (last accessed June29, 2020).
3.
FlotteTR, GaoG. AAV is now a medicine: we had better get this right. Hum Gene Ther, 2017; 28:307.
4.
NaultJC, DattaS, ImbeaudS, et al.Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet, 2015; 47:1187–1193.
5.
BernsKI, ByrneBJ, FlotteTR, et al.Adeno-associated virus type 2 and hepatocellular carcinoma?. Hum Gene Ther, 2015; 26:779–781.
6.
BuningH, SchmidtM. Adeno-associated vector toxicity—to be or not to be?. Mol Ther, 2015; 23:1673–1675.
7.
NaultJC, DattaS, ImbeaudS, et al.AAV2 and hepatocellular carcinoma. Hum Gene Ther, 2016; 27:211–213.
RiordanJD. Re: Srivastava A, Carter BJ; AAV infection: protection from cancer; Hum Gene Ther, 2017; 28:323–327; DOI: 10.1089/hum.2016.147. Hum Gene Ther, 2017; 28:375–376.
10.
SrivastavaA, CarterBJ. Authors' response to Jesse D. Riordan, Hum Gene Ther, 2017; 28:375–376; DOI: 10.1089/hum.2017.045. Hum Gene Ther, 2017; 28:376–377.
11.
KaiserJ. How safe is a popular gene therapy vector?. Science, 2020; 367:131.
12.
GeorgeLA, RagniMV, RaskoJEJ, et al.Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe hemophilia B. Mol Ther, 2020 Jun 10 [Epub ahead of print]; DOI: 10.1016/j.ymthe.2020.06.001.
13.
MannoCS, PierceGF, ArrudaVR, et al.Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med, 2006; 12:342–347.
14.
BlacklowNR, HogganMD, SerenoMS, et al.A seroepidemiologic study of adenovirus-associated virus infection in infants and children. Am J Epidemiol, 1971; 94:359–366.
15.
ZaissAK, CotterMJ, WhiteLR, et al.Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol, 2008; 82:2727–2740.
16.
SrivastavaA. Adeno-associated virus: the naturally occurring virus versus the recombinant vector. Hum Gene Ther, 2016; 27:1–6.
17.
SenderR, FuchsS, MiloR. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol, 2016; 14:e1002533.
BernsKI, SrivastavaA. Next generation of adeno-associated virus vectors for gene therapy for human liver diseases. Gastroenterol Clin North Am, 2019; 48:319–330.
20.
ZhongL, LiB, MahCS, et al.Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A, 2008; 105:7827–7832.
21.
MarkusicDM, HerzogRW, AslanidiGV, et al.High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol Ther, 2010; 18:2048–2056.
22.
LingC, WangY, LuY, et al.Enhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo. J Virol, 2015; 89:952–961.
23.
LingC, LiB, MaW, et al.Development of optimized AAV serotype vectors for high-efficiency transduction at further reduced doses. Hum Gene Ther Methods, 2016; 27:143–149.
24.
MartinoAT, Basner-TschakarjanE, MarkusicDM, et al.Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood, 2013; 121:2224–2233.
25.
SongL, KaussMA, KopinE, et al.Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo. Cytotherapy, 2013; 15:986–998.
26.
SongL, LiX, JayandharanGR, et al.High-efficiency transduction of primary human hematopoietic stem cells and erythroid lineage-restricted expression by optimized AAV6 serotype vectors in vitro and in a murine xenograft model in vivo. PLoS One, 2013; 8:e58757.
27.
LingC, BhukhaiK, YinZ, et al.High-efficiency transduction of primary human hematopoietic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci Rep, 2016; 6:35495.
28.
YangH, QingK, KeelerGD, et al.Enhanced transduction of human hematopoietic stem cells by AAV6 vectors: implications in gene therapy and genome editing. Mol Ther Nucleic Acids, 2020; 20:451–458.
29.
GlushakovaLG, LisankieMJ, EruslanovEB, et al.AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol Genet Metab, 2009; 98:289–299.
30.
LingC, LuY, KalsiJK, et al.Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum Gene Ther, 2010; 21:1741–1747.
31.
VercauterenK, HoffmanBE, ZolotukhinI, et al.Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol Ther, 2016; 24:1042–1049.
32.
BrownHC, DoeringCB, HerzogRW, et al.Development of a clinical candidate AAV3 vector for gene therapy of hemophilia B. Hum Gene Ther, 2020 (in press). DOI: 10.1089/hum.2020.099
